Osteoporosis therapy commonly occurs diseases due to bone mineral density which causes a heavy risk of fractures and bone fragility. Mostly fracture occurs in the hip, spine, shoulder, and forearm. The diagnostic segment is leading include X-ray and radiography tests in anti-osteoporosis therapy.
According to the International Osteoporosis Foundation (IOF), in 2015, one in two women and one in five men aged above 50 years suffered from an osteoporosis-related fracture across the globe. Osteoporosis is a common disorder in women, after menopause risk of osteoporosis and other calcium deficiency diseases increases significantly. Approximately 158 million people were at high risk of fracture in 2010 and the number is expected to rise to 319 million by 2040.
Anti-osteoporosis therapy has lots of side effects and the success rate of the therapy is very low are restrains the growth of the market.
The global anti-osteoporosis therapy and fracture healing market accounted for over USD 22,400 million in 2017 and is expected to grow at a CAGR of 8.4 % during the forecast period, 2019-2026.
The global anti-osteoporosis therapy and fracture healing market are segmented by route of administration and drug type.
On the basis of route of administration, the market is segmented into oral and injectable. Oral is the leading segment over the forecast period. Most of the drugs of this therapy is available in oral form and the oral dosage form is cost-effective.
Based on drug type, the market is segmented into bisphosphonates and selective estrogen receptor modules. The bisphosphonates segment is expected to be the fastest-growing segment throughout the forecast period.
Geographically, the global anti-osteoporosis therapy and fracture healing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).
North America is likely to hold the major market share during the forecast period 2019–2026. According to the International Osteoporosis Foundation (IOF), in 2014, approximately 54% of postmenopausal women were osteopenic and 30% were osteoporotic in the U.S. Osteoporosis is a common problem due to which bones become weaker and there is a higher risk of a fracture during a fall or even a fairly minor knock.
Europe is expected to experience significant growth in the anti-osteoporosis therapy and fracture healing market over the forecast period 2019–2026. The high prevalence of osteoporosis due to physical inactivity and the rising obese population is likely to support the market growth. Changing eating habits and poor nutrition leads to calcium deficiency and different bone diseases which in turn is likely to fuel the market growth.
The Asia Pacific is expected to be the fastest-growing market during the forecast period 2019–2026. Every year in India around 10 million people experience fractures due to osteoporosis. Furthermore, the high prevalence of back pain in women after menopause is likely to support the market growth. Furthermore, growing incidences of calcium deficiency In Japan are propelling market growth.
Latin America accounts for the least share of the global anti-osteoporosis therapy and fractures healing market. The increasing incidence of osteoporosis in Mexico, Brazil, Argentina, Bolivia, Puerto Rico, and Colombia is expected to influence the market growth. In the Middle East and Africa growing population, and rise in per capita income is driving the market.
Some of the major players in the anti-osteoporosis therapy and fracture healing market are F.Hoffmann La Roche Ltd., Actavis plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Merck and Company Inc., Amgen Inc., Novartis International AG., Pfizer, Inc., and GlaxoSmithKline plc.
By Route of Administration
By Drug Type
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Route of Administration, Drug Type|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||F.Hoffmann La Roche Ltd., Actavis plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Merck and Company Inc., Amgen Inc., Novartis International AG., Pfizer, Inc., and GlaxoSmithKline plc.,|
|Key Market Opportunities||High Demand In Healthcare It Sector Is Pushing Anti-Osteoporosis Therapy And Fracture Healing Market|